{{Rsnum
|rsid=11650106
|Gene=VMP1
|Chromosome=17
|position=59772890
|Orientation=plus
|GMAF=0.3944
|Gene_s=VMP1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 18.2 | 50.0 | 31.8
| HCB | 44.4 | 40.0 | 15.6
| JPT | 47.7 | 38.6 | 13.6
| YRI | 85.5 | 14.5 | 0.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 44.4 | 40.0 | 15.6
| CHD | 28.0 | 50.5 | 21.5
| GIH | 33.7 | 42.9 | 23.5
| LWK | 0.0 | 0.0 | 0.0
| MEX | 9.1 | 56.4 | 34.5
| MKK | 70.7 | 26.7 | 2.7
| TSI | 19.2 | 51.5 | 29.3
| HapMapRevision=28
}}{{PMID Auto GWAS
  |PMID=23118302
  |Trait=Lipoprotein-associated phospholipase A2 activity and mass
  |Title=Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy.
  |RiskAllele=C
  |Pval=3E-9
  |OR=.01
  |ORtxt=[0.0039-0.0145] ng/ml decrease
  }}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}